Jazz Pharmaceuticals (JAZZ) Non-Current Debt (2010 - 2026)

Jazz Pharmaceuticals' Non-Current Debt history runs 16 years deep, the most recent figure standing at $4.3 billion for Q1 2026.

• In Q1 2026, Non-Current Debt fell 18.97% year-over-year to $4.3 billion; the TTM figure through Mar 2026 stood at $4.3 billion (down 18.97% YoY), while the FY2025 annual figure was $4.3 billion, down 28.78% from the prior year.
• Non-Current Debt was $4.3 billion for Q1 2026 at Jazz Pharmaceuticals, roughly flat from $4.3 billion in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $6.1 billion in Q3 2024 to a low of $4.3 billion in Q1 2026.
• Historically, Non-Current Debt has averaged $5.3 billion across 5 years, with a median of $5.3 billion in 2025.
• The sharpest annual moves came in 2022 and 2025: Non-Current Debt surged 223.41% in 2022, then dropped 28.78% in 2025.
• A 5-year view of Non-Current Debt shows it stood at $5.7 billion in 2022, then slipped by 10.28% to $5.1 billion in 2023, then advanced by 18.98% to $6.1 billion in 2024, then retreated by 28.78% to $4.3 billion in 2025, then retreated by 0.1% to $4.3 billion in 2026.
• The last three Non-Current Debt figures came in at $4.3 billion (Q1 2026), $4.3 billion (Q4 2025), and $4.3 billion (Q3 2025), per Business Quant data.